{"filings":[{"id":95653,"accession_number":"0001809519-26-000110","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GoodRx Q1 revenue $194M, raises FY2026 guidance; Pharma Direct up 82% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $194.0M; net income $1.2M; adjusted EBITDA $58.3M (30.0% margin).","Pharma Direct Revenue increased 82% YoY, leading growth momentum.","Company raises full year 2026 revenue and adjusted EBITDA expectations.","Adjusted Net Income $23.0M; Adjusted Net Income Margin 11.9%.","Net cash from operating activities $11.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":194006000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95652,"accession_number":"0001809519-26-000080","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GoodRx appoints Thomas Chan as Chief Accounting Officer effective April 23, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Chan, previously VP Corporate Controller, named Chief Accounting Officer and principal accounting officer.","Annual base salary increased to $310,000 with target bonus of 40% of base salary.","Granted RSU award valued at $131,250 and PSU award valued at $43,750 under 2020 Incentive Award Plan.","Chan joined GoodRx in October 2020 and is a CPA with prior experience at Deloitte & Touche."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95651,"accession_number":"0001809519-26-000071","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Ian T. Clark resigns from GoodRx board; Wendy Barnes moves to Class III","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian T. Clark resigned from the Board and Nominating & Governance Committee effective March 31, 2026.","Clark stated his resignation was not due to any disagreement with the Company or management.","To rebalance board classes, Wendy Barnes resigned as Class I and was immediately re-elected as Class III director on April 1-2, 2026.","Board now has three directors in each class (I, II, III)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108862,"accession_number":"0001809519-26-000064","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GoodRx CAO Romin Nabiey resigns effective April 3, 2026; transition through June 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Romin Nabiey resigned as Chief Accounting Officer, effective April 3, 2026, to pursue other opportunities.","He will remain an employee through June 8, 2026 to assist with transition of responsibilities.","Resignation not due to any disagreement with Company regarding operations, policies, or practices.","No successor has been announced for the Chief Accounting Officer role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108861,"accession_number":"0001809519-26-000059","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"GoodRx replaces PwC with KPMG as independent auditor for FY2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee appointed KPMG as independent auditor for FY2026, replacing PwC.","PwC's audit reports for FY2024 and FY2025 were unqualified; no disagreements or reportable events.","No prior consultations with KPMG on accounting principles or audit matters.","Change follows a competitive proposal process; PwC provided an SEC letter confirming agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108860,"accession_number":"0001809519-26-000051","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GoodRx Holdings Approves $72,918 Cash Bonus for Chief Accounting Officer Romin Nabiey","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved a discretionary cash bonus of $72,918 for Romin Nabiey, Chief Accounting Officer, for 2025 performance.","Approval occurred on March 3, 2026, following the Compensation Committee's recommendation.","The bonus is part of compensatory arrangements for an executive officer at GoodRx Holdings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108859,"accession_number":"0001809519-26-000039","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GoodRx director Dipanjan Deb resigns from board effective Feb 26, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dipanjan Deb resigned as a member of GoodRx's Board of Directors effective February 26, 2026.","Company states resignation is not due to any disagreement with operations, policies, or management.","No replacement director announced; remaining board composition unchanged per filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108858,"accession_number":"0001809519-26-000028","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GoodRx reports Q4 revenue $194.8M, Adj. EBITDA $65.0M; Pharma Direct grows >40% YoY for 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $194.8M, net income $5.4M, Adjusted EBITDA $65.0M (33.4% margin).","Full-year 2025 revenue $796.9M, net income $30.4M, Adjusted EBITDA $270.5M (33.9% margin).","Pharma Direct revenue beat prior outlook with over 40% year-over-year growth in 2025.","CEO Wendy Barnes notes strong finish, rebranded Pharma Manufacturer Solutions as Pharma Direct.","Adjusted Net Income Q4 $29.0M (14.9% margin); FY $126.1M (15.8% margin)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":796853000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125322,"accession_number":"0001809519-25-000156","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GoodRx grants $3M retention bonuses to CEO and CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Wendy Barnes receives $2M retention bonus; CFO Chris McGinnis receives $1M.","Bonuses payable within 15 days of Dec 9, 2025 execution; subject to clawback if employment ends for cause or without good reason before Dec 31, 2027.","Full after-tax repayment if termination before Dec 31, 2026; 50% if between Jan 1, 2027 and Dec 31, 2027.","Executives waive participation in 2025 executive bonus plan and any annual incentive program for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125321,"accession_number":"0001809519-25-000141","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GoodRx Q3 revenue $196M, net income $1.1M; raises manufacturer solutions outlook to ~35% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $196.0M; net income $1.1M (0.6% margin).","Adjusted EBITDA $66.3M (33.8% margin); Adjusted Net Income $28.8M (14.7% margin).","Raises Pharma Manufacturer Solutions revenue growth outlook to ~35% YoY for FY2025; maintains total revenue and adjusted EBITDA guidance.","Net cash from operations of $76.0M in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":602068000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125320,"accession_number":"0001809519-25-000136","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GoodRx Co-Chairman Trevor Bezdek ends executive employment, remains as non-employee director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment terminated by mutual agreement on Nov 1, 2025; Bezdek stays as Co-Chairman of the Board.","As non-employee director, receives annual cash retainers: $30K for Board, $10K for Nominating/Governance, $75K for Co-Chair.","One-time RSU award of $420K (vests over 3 yrs) and additional RSU award of $134K (vests by June 2026 or 2026 annual meeting).","Eligible to participate in Deferred Compensation Plan for directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142032,"accession_number":"0001809519-25-000115","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GoodRx Q2 revenue $203.1M, Adj. EBITDA $69.4M; pharma segment up 32% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $203.1M, net income $12.8M (6.3% margin); adjusted net income $33.9M (16.7% margin).","Adjusted EBITDA $69.4M (34.2% margin); operating cash flow $49.6M.","Pharma Manufacturer Solutions revenue +32% YoY; new pharmacy counter deals and ED subscription launched.","Results in line with prior guidance; no explicit revision to outlook provided."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":406040000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160004,"accession_number":"0001809519-25-000088","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GoodRx stockholders elect three Class II directors and ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Christopher Adams, Trevor Bezdek, and Scott Wagner as Class II directors; each received >2.6B votes for.","Ratified PricewaterhouseCoopers as independent auditor for FY 2025; 99.9% voted for (2.66B for).","Advisory say-on-pay approved with 2.62B votes for (99.9% of votes cast excluding abstentions).","Total voting power at meeting represented ~99.5% of outstanding shares; Class B shares hold 10 votes each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160003,"accession_number":"0001809519-25-000073","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GoodRx Q1 2025 revenue in-line at $203M; raises FY adjusted EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $203.0M, net income $11.1M (net income margin 5.4%).","Adjusted EBITDA $69.8M (34.4% margin) beat guidance; FY adjusted EBITDA expectations raised.","Adjusted Net Income $34.4M (16.9% margin).","Maintains FY 2025 revenue guidance range.","Over 7 million consumers of prescription-related offerings at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":202970000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178334,"accession_number":"0001809519-25-000055","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GoodRx to repurchase 20M shares from three major holders at $4.20/share (5% discount)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchases 3M shares from Spectrum, 10M from Francisco Partners, and 7M from Idea Men; total 20M shares.","Price of $4.20/share represents ~5% discount to March 14 close of $4.42; expected close March 21.","Part of existing $450M buyback program; ~$198.3M remains available after transaction costs.","Sellers agree to lock-up until second trading day after Q1 2025 earnings release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178333,"accession_number":"0001809519-25-000035","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GoodRx reports Q4 revenue $198.6M, net income $6.7M; full-year revenue $792.3M, Adj. EBITDA $260.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue of $198.6M, net income $6.7M (3.4% margin), Adjusted EBITDA $67.1M (33.8% margin).","Full year 2024 revenue $792.3M, net income $16.4M (2.1% margin), Adjusted EBITDA $260.2M (32.8% margin).","Q4 operating cash flow $44.7M, full-year $183.9M; over 7 million prescription consumers at quarter end.","Results described as substantially in-line with previous guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":792324000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178332,"accession_number":"0001809519-25-000021","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GoodRx names Christopher McGinnis as CFO, effective Feb 4, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["McGinnis was CEO of Citizens Rx; succeeds Romin Nabiey (interim CFO), who remains CAO.","Base salary of $500,000; eligible for annual cash bonus targeted at 100% of base salary.","One-time signing bonus of $250,000; must remain employed through first anniversary or repay pro-rata.","Equity awards totaling $7M: $3.5M RSU and $3.5M option; vest 25% on Feb 15, 2026 then quarterly over 4 years.","McGinnis becomes a Tier 1 participant in the Executive Severance Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178331,"accession_number":"0001809519-25-000015","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GoodRx appoints Scott Wagner as director, co-chair; Simon Patterson resigns from board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Wagner appointed Class II director, Chair of Compensation Committee, and Co-Chair of the Board effective Jan 21, 2025.","Wagner previously served as GoodRx Interim CEO from April 2023 to January 2025.","Simon Patterson resigned as director, not due to any disagreement with Company or management.","Vacancy filled by Silver Lake Stockholders exercising board designation rights; Wagner appointed.","Wagner receives standard non-employee director compensation: initial RSU award of $420,000 and pro-rated annual RSU of $85,699."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178330,"accession_number":"0001193125-25-005050","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GoodRx CFO Karsten Voermann resigns; CAO Romin Nabiey named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karsten Voermann resigns as CFO effective Jan 17, 2025, for personal reasons, not due to any disagreement.","Romin Nabiey, current Chief Accounting Officer, appointed Interim CFO and principal financial officer.","Nabiey will continue as CAO; has been with GoodRx since 2017 in various finance roles.","Voermann's vested stock options remain exercisable through Jan 17, 2026; he retains earned 2024 bonus.","Company begins search for permanent CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194996,"accession_number":"0001809519-24-000213","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GoodRx appoints Wendy Barnes as CEO and President, effective Jan 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wendy Barnes named CEO/President, succeeding interim CEO Scott Wagner; also elected Class I director.","Base salary of $825,000, target bonus 100% of salary, and a $550,000 signing bonus.","Equity grants: $9M RSU, $9M option, and $2M additional RSU, vesting over time.","Severance: 12-18 months base salary plus COBRA for 18 months, with accelerated vesting on change of control.","Barnes previously CEO of RxBenefits and President of Express Scripts; holds biochemistry degree."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194995,"accession_number":"0001809519-24-000194","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GoodRx Q3 2024 revenue $195.3M, net income $4.0M, Adjusted EBITDA $65.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue and Adjusted Revenue both $195.3 million for Q3 2024.","Net income of $4.0 million (2.0% margin); Adjusted Net Income $31.9 million (16.4% margin).","Adjusted EBITDA $65.0 million (33.3% margin); operating cash flow $86.9 million.","Exited Q3 with over 7 million consumers of prescription-related offerings.","Expects ~20% YoY growth in pharma manufacturer solutions for Q4 2024 and 20%+ for FY 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":593741000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194994,"accession_number":"0001809519-24-000188","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"GoodRx adds IQVIA CFO Bruehlman to board; Bezdek extends contract with no severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ronald E. Bruehlman (IQVIA CFO) elected to Board and as Audit & Risk Committee chair, effective Nov 8, 2024.","Director Julie Bradley resigns Nov 8 due to personal commitments; no disagreement with company.","Chief Mission Officer Douglas Hirsch ends employment Oct 25; stays on Board as non-employee director.","Chairman Trevor Bezdek's employment extended through Oct 25, 2025; 2025 cash bonus target 100% of salary; no severance.","Bruehlman receives $420K RSU (3-year vest) and $132K pro-rated annual RSU; eligible for standard director cash retainers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211286,"accession_number":"0001809519-24-000162","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GoodRx reports Q2 2024 revenue $200.6M, net income $6.7M, adjusted EBITDA $65.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue and Adjusted Revenue of $200.6M for Q2 2024.","Net income of $6.7M (3.3% margin); Adjusted Net Income of $32.4M (16.1% margin).","Adjusted EBITDA of $65.4M (32.6% margin).","Net cash from operations $9.7M; over 7M consumers of prescription offerings.","Interim CEO Scott Wagner noted progress in retail/PBM partnerships and brand medication scaling."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":398490000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211285,"accession_number":"0001809519-24-000147","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"GoodRx enters Sixth Amendment to Credit Agreement, refinances $500M term loan facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $500M 2024 Term Loan Facility matures July 2029 with SOFR + 3.75% margin, used to repay Existing Term Loans ($167.2M cash added).","Maturity of $88M of $100M revolving credit facility extended to April 2029; remaining $12M terminates July 2025.","Quarterly principal payments of 0.25% of original principal beginning Q2 2024, prepayment premium 1.00% if before Jan 2025.","Financial covenant requires First Lien Net Leverage Ratio not exceeding 8.2x if revolving borrowings exceed threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211284,"accession_number":"0001809519-24-000133","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"GoodRx adds former Genentech CEO Ian Clark to board, creates Innovation Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian T. Clark elected Class III director effective July 8, 2024; fills vacancy from Stephen LeSieur's March resignation.","Clark chairs newly created Innovation Committee; also joins Nominating and Corporate Governance Committee.","Granted initial RSU award worth $420,000 and pro-rated annual award of $209,836 under director compensation plan.","Board combined Audit and Compliance committees into a single Audit and Risk Committee.","Clark brings 35+ years pharma/healthcare experience; board deems him independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229845,"accession_number":"0001809519-24-000104","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GoodRx stockholders elect three Class I directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Douglas Hirsch, Kelly J. Kennedy, and Agnes Rey-Giraud as Class I directors for terms through 2027.","Ratified appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal 2024.","Advisory vote approved named executive officer compensation (2.82B votes for, 4.15M against).","Over 98.7% of combined voting power represented at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229844,"accession_number":"0001809519-24-000094","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"GoodRx elects Simon Patterson to fill board vacancy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simon Patterson elected as Class II director effective May 29, 2024, term expires at 2025 annual meeting.","Patterson, a Managing Director at Silver Lake, joins Nominating and Corporate Governance Committee.","He fills vacancy left by Adam Karol's March 22 resignation; Silver Lake retains right to designate one director.","Patterson brings tech investment and board experience from Dell Technologies, Skype, and others.","No compensation for board service; standard indemnification agreement entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229843,"accession_number":"0001809519-24-000081","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GoodRx Q1 2024 revenue $197.9M; adjusted EBITDA $62.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue (GAAP and adjusted) of $197.9M; net loss $1.0M; adjusted net income $32.6M.","Adjusted EBITDA $62.8M (31.7% margin); operating cash flow $42.6M.","Exited Q1 with ~8 million consumers of prescription-related offerings.","Interim CEO Scott Wagner cites progress and path to return to 'Rule of 40' company."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":197880000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248320,"accession_number":"0001809519-24-000048","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"GoodRx interim CEO Scott Wagner extends commitment; two board directors resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Wagner's employment agreement revised to indefinite term, annual cash bonus target 100% of base salary.","Wagner granted $8M in equity ($4M options, $4M RSUs) vesting monthly over eight months starting May 8, 2024.","Stephen LeSieur resigns from board effective March 14, 2024; Adam Karol resigns effective March 22, 2024.","Both directors cited no disagreement; LeSieur departure follows repurchase of Spectrum shares from him."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248319,"accession_number":"0001809519-24-000041","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GoodRx CFO Karsten Voermann enters new employment agreement, receives $5M equity and special bonus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New agreement sets base salary at $450,000, target bonus of 100% of salary, and $5M equity award (50% option, 50% RSU) vesting over 4 years.","One-time special bonus of $162,792 for contributions to restructuring and management transition.","Severance provides 12 months base salary, COBRA reimbursement, and accelerated vesting for 12 months if terminated without cause in change-of-control period.","Voermann remains at-will and subject to confidentiality, non-solicitation covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248318,"accession_number":"0001193125-24-061365","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GoodRx repurchases 20.9M shares from Spectrum, Francisco Partners at $7.19, discount to $7.57 close","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchases 6,239,942 shares from Spectrum and 14,622,366 from Francisco Partners, total 20,862,308 shares.","Price of $7.19 per share is 5% discount to $7.57 closing price on March 6, 2024.","Total cost approximately $150M; about $299.6M remains under existing $450M buyback program.","Spectrum and Francisco Partners agree not to trade shares until after Q1 2024 earnings release.","Closing expected on or about March 11, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248317,"accession_number":"0001809519-24-000029","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GoodRx Q4 revenue $196.6M; net loss $25.9M; adj. EBITDA $57.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $196.6M, net loss $25.9M (13.2% margin), adjusted net income $31.1M (15.8% margin).","Full year 2023 revenue $750.3M, net loss $8.9M, adjusted EBITDA $217.4M (28.6% margin).","Q4 net cash from operations $15.9M; exited with over 7M consumers of prescription offerings.","Interim CEO Scott Wagner expects continued topline growth in Q1 and full year 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":750265000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248316,"accession_number":"0001809519-24-000020","cik":1809519,"company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["1.01","2.03","5.02","9.01"],"status":"ready","headline":"GoodRx extends $100M revolver to July 2025, COO Raj Beri departs with severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Revolver maturity extended from Oct 11, 2024 to July 11, 2025; other terms unchanged.","COO Raj Beri removed effective Feb 15, 2024; role eliminated.","Beri to receive $1.134M cash severance (base salary + bonus) plus $375K discretionary bonus.","Immediate vesting of 111,776 stock options at $5.94; extended exercise period for other options.","COBRA premiums reimbursed for 12 months; Beri signed release and non-disparagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1002479077.3986014,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}